Last night, AI finally did something human-like.

It didn't help the boss cut programmers.

It helped doctors issue a wanted notice for cancer cells.

Merck and Moderna just announced a significant phase three result:

For melanoma patients who have undergone surgery but have a very high risk of recurrence,

personalized mRNA therapy

KEYTRUDA

outperformed using KEYTRUDA alone

in terms of “Will the cancer come back?” and “Will it metastasize?”

Don't rush to shout:

AI has conquered cancer.

Strictly speaking, AI here is not a doctor, nor a drug.

It resembles a particularly skilled investigative team.

The doctor first takes the patient's tumor and normal tissue for sequencing.

Every person's tumor will have a myriad of confusing mutations.

The question is:

Which specific mutations

most resemble the fingerprints left by cancer cells?

Which are the most worthy targets for the immune system to chase?

This is the job of the algorithm.

It filters out up to 34 targets that are more likely to be recognized by the immune system from a pool of candidates.

Then Moderna writes this “wanted notice”

into a dose of mRNA.

mRNA doesn’t directly attack cancer cells.

It simply trains T cells:

If you see these features,

don’t hold back, go ahead and grab them.

And KEYTRUDA's role

is more like releasing the brakes that T cells were originally stepping on.

One is responsible for recognizing people.

One is responsible for letting them go.

So, the most shocking part this time is not just another vaccine shot.

But it's that this process has been completed for the first time:

tumor sequencing

→ algorithm targeting

→ designing mRNA specifically for one person

→ training the immune system

→ seeing clinical results in phase three trials

The COVID-19 mRNA vaccine was like giving the same test paper to the entire world.

This time, each patient received a unique test,

with different questions.

Of course, maintaining calm is essential.

What has been announced are top-line results; complete data is yet to come.

Overall survival is still under observation.

It is not “one shot cures all cancers,” and certainly not AI acting alone.

But this at least proves one point:

The truly valuable direction for AI

is not to write human nonsense faster.

But to slowly turn the most challenging statement,

“Everyone's illness is different,”

into a verifiable and manufacturable treatment path.

免责声明：本文章仅代表作者个人观点，不代表本平台的立场和观点。本文章仅供信息分享，不构成对任何人的任何投资建议。用户与作者之间的任何争议，与本平台无关。如网页中刊载的文章或图片涉及侵权，请提供相关的权利证明和身份证明发送邮件到support@aicoin.com，本平台相关工作人员将会进行核查。